Tag: covid vaccine

1. A case series of 22 patients found that women and patients with an allergy history were more likely to have experienced an anaphylactic reaction to the mRNA COVID-19 vaccine. 2. An IgG-mediated reaction to polyethylene glycol (PEG) was found to be the most frequent mechanism of reactivity amongst this...
1. An interval of 44-45 weeks between the first and second dose resulted in a four-fold increase in median antibody titers, 28-days after administration, compared to the standard interval of 8-12 weeks. 2. A two-fold increase in median IgG levels was observed among patients 28-days after receiving their third dose...
1. Heterologous AstraZeneca followed by Pfizer vaccination was noninferior to homologous, two-dose AstraZeneca vaccination with a geometric mean ratio of 9.2. 2. Heterologous Pfizer followed by AstraZeneca vaccination was not found to be non-inferior to homologous, two-dose Pfizer vaccination. Evidence Rating Level: 1 (Excellent) Study Rundown: Heterologous prime-boost vaccination schedules involve administering...
1. In a large national survey, more than half of U.S. parents reported hesitancy in vaccinating their children against COVID-19. 2. Pediatric physicians were found to be the most trusted source of information about the COVID-19 vaccine. Evidence level: 2 (good) Study Rundown: Vaccines provide an effective prevention against illness caused by...
1. An interim analysis of post-vaccination surveillance data for individuals who had received either Pfizer or Moderna mRNA COVID-19 vaccinations found that rates of serious adverse events did not differ between the 1-21 day and 22-42 day post-vaccination periods, respectively. Evidence Rating Level: 2 (Good) Study Rundown: The development of mRNA...
1. The findings of this prospective cohort study suggested poor humoral immune response following a single dose of the BNT162b2 COVID-19 vaccine in the hemodialysis patient population compared to two doses. 2. Based on the findings in this study, the second vaccine dose should not be delayed in patients receiving...
Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 group compared to control. There were no vaccine-related serious adverse events. Evidence Rating Level: 1 (Excellent)  Study Rundown: Current research on COVID-19 vaccination has revolved around a homologous dosing schedule (administering the...
1. Incidence of PCR-confirmed symptomatic COVID-19 cases was lower in the vaccine group compared with the placebo group (p<0.0001). 2. The majority of adverse events were mild and there was no vaccine-related mortality.  Evidence Rating Level: 1 (Excellent) Study Rundown: Inactivated vaccines offer a variety of benefits against transmission of severe acute...
1. Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 group compared to control. 2. There were no vaccine-related serious adverse events. Evidence Rating Level: 1 (Excellent)  Study Rundown: Current research on COVID-19 vaccination has revolved around a homologous dosing schedule (administering...
1. After receiving the BNT162b2 SARS-CoV-2 vaccine, fewer cancer patients demonstrated seropositivity for COVID antibodies compared to age-matched healthy controls, but those that were seropositive had comparable titers to healthy controls. 2. The COVID vaccine was found to have an acceptable safety profile amongst cancer patients currently on treatment, with...